Comparison of Stereotactic Body Radiation Therapy for Biopsy-Proven versus Radiographically Diagnosed Early-Stage Non-Small Lung Cancer: A Single-Institution Experience
| Autor: | Sanford R. Katz, Hunter Boggs, Sahaja Acharya, Lane R. Rosen, Michael Durci, Benjamin W. Fischer-Valuck |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms Stereotactic body radiation therapy Biopsy medicine.medical_treatment Kaplan-Meier Estimate Radiosurgery Disease-Free Survival Medical Records Fluorodeoxyglucose F18 Carcinoma Non-Small-Cell Lung medicine Humans Stage (cooking) Single institution Aged Neoplasm Staging Retrospective Studies medicine.diagnostic_test business.industry General Medicine Middle Aged Surgery Radiation therapy Oncology Lymphatic Metastasis Positron-Emission Tomography Non small lung cancer Female Non small cell Radiopharmaceuticals Tomography X-Ray Computed business Follow-Up Studies |
| Zdroj: | Tumori Journal. 101:287-293 |
| ISSN: | 2038-2529 0300-8916 |
| Popis: | Introduction Histological confirmation of non-small cell lung cancer (NSCLC) is often required before patients are offered stereotactic body radiation therapy (SBRT) as a treatment option. Many patients, however, are unsuitable to undergo a biopsy procedure because of comorbidity. Our objective is to compare the outcomes of patients with biopsy-proven (BxPr) or clinically/radiographically diagnosed (RadDx) early-stage NSCLC treated with SBRT. Methods Records of 88 patients treated with SBRT at a single institution were reviewed. Sixty-five patients had BxPr early-stage NSCLC. Twenty-three patients were RadDx with early-stage NSCLC based on an FDG-avid chest nodule on PET scan, serial sequential CT-findings compatible with NSCLC, and consensus of a multidisciplinary team. Outcomes of patients with BxPr and RadDx NSCLC were evaluated in regard to local control, regional lymph node metastasis-free and distant metastasis-free rates, and overall survival using Kaplan-Meier survival curves. Results Median follow-up for all patients was 29 months (range, 4–82 months). Cumulative local progression-free rate after 3 years for the BxPr group was 93.1% (95% confidence interval [CI], 85.2%-97.6%) and 94.10% (95% CI, 73.2%-97.6%) for the RadDx group (p = 0.98). No differences regarding regional lymph node metastasis-free and distant metastasis-free rates by subgroup were observed. The overall 3-year survival rate for the BxPr group was 59.9% (95% CI, 44.8%-68.2%) and 58.9% (95% CI, 40.1%-77.8%) for the RadDx group (p = 0.46). Conclusions SBRT is a practical treatment modality for patients with RadDx early-stage NSCLC. Outcomes of patients RadDx with NSCLC mirror the results of patients treated with BxPr disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|